REMUS PHARMACEUTICALS LIMITED (REMUS): Financials & Fundamentals History

Share Price

₹843.35

P/E

26.9x

ROCE

17.0%

Market Cap

₹994 cr

Revenue (TTM)

₹854 cr

P/S

1.2x

P/B

2.8x

ROE

10.5%

Debt / Equity

0.1x

Promoter Holding

71.0%

12M Momentum

17.1%

P/E vs its own history17th percentilesince Jun '24

P/E vs Health Technology0.8xthe sector median

52-week range

₹580.00₹1039.00

57% of the way from its 52-week low to its high

Price risk

1Y volatility

56.1%

Beta vs sector

1-year daily

0.78

Balance sheet & cash

Interest cover

operating profit ÷ interest

61.0x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.27x

low

Share count, 1Y

unchanged

Was the rally earned?

+17%share price, 1 yearLower P/E held it back

Mostly yes, with a catch.

Per-share earnings added 26 points, but investors now pay less per rupee of profit (P/E 29.2x to 26.9x), which took 9 points back.
The share count fell 5%.

Net profit growth+21 ptsNet profit rose about 21%, which lifts the price.

P/E change-9 ptsThe P/E fell from 29.2x to 26.9x, which lowers the price.

Share count change+6 ptsShare count fell 5%, which lifts the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with RUBICON RESEARCH

Is it expensive against its own past and its peers?

26.9xP/E todayNear its historic low

Against its own history17th percentileMedian 36.2x; usual range 26.1x to 74.0x since 2024-06.

Against Health Technology26.9x vs 35.4xBelow the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dashed line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

What is the price implying?

~19%annual earnings growth implied by the price

At a P/E of 26.9x, the price would imply about 18.5%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

Oct '26Volume reached 10.4x its 50-day median on 2026-10-08; price +14.2% that day.
Aug '26Volume reached 23.0x its 50-day median on 2026-08-07; price +3.9% that day.
Jun '26Revenue (TTM) reached a new high of ₹854 cr.
Jun '26P/E fell below the 10th percentile of its own history to date (24.8x).
Jun '26Slipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
May '26Volume reached 20.4x its 50-day median on 2026-05-15; price +20.0% that day.
Mar '26Fell 57% from the Oct 2024 peak to the Mar 2026 low.
Jan '26Volume reached 14.8x its 50-day median on 2026-01-02; price +10.9% that day.

Show 12 earlier events

Oct '25Volume reached 14.5x its 50-day median on 2025-10-07; price -3.8% that day.
Aug '25Volume reached 5.5x its 50-day median on 2025-08-19; price +0.3% that day.
Jun '25Revenue (TTM) reached a new high of ₹620 cr.
Jun '25Share count is up 200.0% over 12 months.
Feb '25Volume reached 6.2x its 50-day median on 2025-02-03; price -14.8% that day.
Nov '24Volume reached 5.7x its 50-day median on 2024-11-29; price -0.5% that day.
Jul '24Volume reached 7.8x its 50-day median on 2024-07-05; price +9.9% that day.
Apr '24Regained the 2023-12 peak, 1 month after the low.
Apr '24Volume reached 15.0x its 50-day median on 2024-04-24; price +19.6% that day.
Mar '24Fell 36% from the Dec 2023 peak to the Mar 2024 low.
Mar '24Volume reached 5.0x its 50-day median on 2024-03-06; price -0.5% that day.
Dec '23Volume reached 5.3x its 50-day median on 2023-12-15; price +8.6% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

5 of 6 checks are within range, 1 beyond a threshold.
Tap a check to see how it is measured.

Other income reliance12%Within range

Other income as a share of pre-tax profit (trailing twelve months): 11.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion0.27xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: 0.27x (cash from operations ₹29 cr, net profit ₹108 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 3 yrsWithin range

Fiscal years with positive free cash flow in the last 3: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-71 daysWithin range

Debtor days are below the median of the previous three fiscal years by 71 days (60 vs 131). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress44% of fixed assetsWithin range

Capital work-in-progress is 44% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-172 days / 2 yrsWithin range

Days payable changed by -172 over two years. Bands: rise of up to 30 days; more than 30 days.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, FIIs added 2.9 pts; promoters added 1.3 pts.
The number of shareholders rose from 856 to 2,009 (+135%) between Sep 2023 and Mar 2026.

Holdings, Mar '26

How each group changed

GroupSep '23Mar '26Change

Promoters69.6%71.0%+1.3 pts

FIIs2.4%5.3%+2.9 pts

DIIs0.7%0.8%+0.1 pts

Public and others27.3%22.9%-4.4 pts

Number of shareholders

2,009shareholders+135% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-57.2%not yet recovered

1-year volatility56.1%annualised

Beta vs sector index0.993-year daily, correlation 0.27

Volume spikes9last 90 sessions, 5x the 50-day median

Monthly share price

Last 90 trading days

Drawdown from peak

Largest drawdowns

-57.2% (2024-10 peak to 2026-03 low, not yet recovered)

-36.2% (2023-12 peak to 2024-03 low, recovered 2024-04)

-20.0% (2023-07 peak to 2023-07 low, recovered 2023-07)

Most recent volume spikes

2026-10-14: 5.5x the 50-day median, price +10.4% that day

2026-10-08: 10.4x the 50-day median, price +14.2% that day

2026-09-17: 9.1x the 50-day median, price +12.2% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26

Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

Company	Sector	Similarity	Closest on
VILAS TRANSCORE (VILAS)	Producer Manufacturing	71%	ROCE, market cap
DANISH POWER (DANISH)	Producer Manufacturing	57%	P/E, promoter holding
EPACK PREFAB TECHNOLOGIES (EPACKPEB)	Producer Manufacturing	53%	P/E, debt/equity
ORBIT EXPORTS (ORBTEXP)	Process Industries	53%	debt/equity, volatility
GOODYEAR INDIA (GOODYEAR)	Consumer Durables	50%	ROCE, P/E
NOVARTIS INDIA (NOVARTIND)	Health Technology	37%	promoter holding, ROCE
ANLON HEALTHCARE (AHCL)	Health Technology	30%	market cap, volatility
KILITCH DRUGS (I) (KILITCH)	Health Technology	29%	P/E, market cap

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What happened next to similar setups

−1.0%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like REMUS PHARMACEUTICALS LIMITED today on valuation, return on capital, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −20% to +31% vs the market, against −1% for all non-financial companies in the same months.
The gap against the base rate (−0.1%, 80% range −7.6% to +9.7%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 10 beyond the range shown, drawn at the edge

Similar setups' median

−1.0%

All companies' median

−0.9%

Beat the market

50% vs 49%

50 past situations · 50 companies · 35 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MOREPENLAB Health Technology	Aug 2024	42x	17%	+105%	−2%	−37%
WINDLAS Health Technology	Jul 2025	34x	17%	+20%	−14%	−18%
IFGLEXPOR Producer Manufacturing	Jul 2021	23x	14%	+282%	−2%	−37%
NDRAUTO Producer Manufacturing	May 2024	35x	17%	+104%	−9%	+100%
AUTOAXLES Producer Manufacturing	Sep 2022	40x	17%	+56%	−11%	−2%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
DODLA Consumer Non-Durables	Apr 2024	47x	16%	+94%	−7%	+6%
GABRIEL Producer Manufacturing	Jul 2024	40x	—	+122%	−2%	+121%
GAEL Consumer Non-Durables	Nov 2020	19x	—	+61%	−4%	−7%

How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and ROCE. Not used (unavailable for this company): operating margin. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to REMUS PHARMACEUTICALS LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Monthly history (29 months)

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-10	26.9x	₹854 cr	10.5%	17.0%	0.1x
2026-09	28.8x	₹854 cr	10.5%	17.0%	0.1x
2026-08	28.7x	₹854 cr	10.5%	17.0%	0.1x
2026-07	22.9x	₹854 cr	10.5%	17.0%	0.1x
2026-06	24.8x	₹854 cr	10.5%	17.0%	0.1x
2026-05	28.3x	₹620 cr	11.9%	20.0%	0.1x
2026-04	27.8x	₹620 cr	11.9%	20.0%	0.1x
2026-03	25.5x	₹620 cr	11.9%	20.0%	0.1x
2026-02	27.2x	₹620 cr	11.9%	20.0%	0.1x
2026-01	26.2x	₹620 cr	11.9%	20.0%	0.1x
2025-12	28.5x	₹620 cr	11.9%	20.0%	0.1x
2025-11	28.0x	₹620 cr	11.9%	20.0%	0.1x
2025-10	29.2x	₹620 cr	11.9%	20.0%	0.1x
2025-09	29.2x	₹620 cr	11.9%	20.0%	0.1x
2025-08	36.2x	₹620 cr	11.9%	20.0%	0.1x
2025-07	37.4x	₹620 cr	11.9%	20.0%	0.1x
2025-06	40.0x	₹620 cr	11.9%	20.0%	0.1x
2025-05	59.0x	₹213 cr	12.3%	—	0.1x
2025-04	57.1x	₹213 cr	12.3%	—	0.1x
2025-03	63.3x	₹213 cr	12.3%	—	0.1x
2025-02	60.8x	₹213 cr	12.3%	—	0.1x
2025-01	67.5x	₹213 cr	12.3%	—	0.1x
2024-12	70.6x	₹213 cr	12.3%	—	0.1x
2024-11	76.6x	₹213 cr	12.3%	—	0.1x
2024-10	74.0x	₹213 cr	12.3%	—	0.1x
2024-09	74.1x	₹213 cr	12.3%	—	0.1x
2024-08	76.3x	₹213 cr	12.3%	—	0.1x
2024-07	60.3x	₹213 cr	12.3%	—	0.1x
2024-06	57.9x	₹213 cr	12.3%	—	0.1x

Methodology and data notes